Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Woman and Man Max 99 years
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Update Il y a 4 ans
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney disease
To characterize the long-term safety and tolerability of AMG 416 in the treatment of SHPT in subjects with chronic kidney disease on hemodialysis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Update Il y a 4 ans
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney disease
To evaluate the efficacy and safety of AMG 416 in the treatment of secondary hyperparathyroidism (SHPT) in subjects with chronic kidney disease (CKD) on hemodialysis. Primary: To evaluate the effi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Update Il y a 4 ans
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney disease
To characterize the long-term safety and tolerability of AMG 416 in the treatment of SHPT in subjects with CKD on hemodialysis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
Update Il y a 4 ans
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidism
Demonstrate that treatment with AMG 416 is not inferior to treatment with cinacalcet for lowering plasma intact parathyroid hormone (PTH) levels by > 30% from baseline among subjects with chronic kidn...
Country
None
organs
None
Specialty
None
Closed trial
More information